Impact of gender in primary prevention of coronary heart disease with statin therapy: A meta-analysis

International Journal of Cardiology

Volumn 138, Issue 1, 2010, Pages 25-31

  Petretta, Mario ^a   Costanzo, Pierluigi ^a   Perrone Filardi, Pasquale ^a   Chiariello, Massimo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Coronary heart disease; Gender; Primary prevention; Statins

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY RISK; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

CORONARY DISEASE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; SEX CHARACTERISTICS;

EID: 70749087459     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.08.001     Document Type: Article

References (32)

1. Bello N., and Mosca L. Epidemiology of coronary heart disease in women. Prog Cardiovasc Dis 46 (2004) 287-295
2. Mosca L., Banka C.L., Benjamin E.J., et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 115 (2007) 1481-1501
3. Kim C., Hofer T.P., and Kerr E.A. Review of evidence and explanations for suboptimal screening and treatment of dyslipidemia in women. A conceptual model. J Gen Intern Med 18 (2003) 854-863
4. Persell S.D., Maviglia S.M., Bates D.W., and Ayanian J.Z. Ambulatory hypercholesterolemia management in patients with atherosclerosis. Gender and race differences in processes and outcomes. J Gen Intern Med 20 (2005) 123-130
5. Walsh J.M.E., and Pignone M. Drug treatment of hyperlipidemia in women. JAMA 291 (2004) 2243-2252
6. Mizuno K., Nakaya N., Ohashi Y., et al. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA study). Circulation 4 (2008) 494-502
7. Moher D., et al., for the QUOROM Group. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet 354 (1999) 1896-1900
8. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 (1996) 1-12
9. Furberg C.D., Adams Jr. H.P., Applegate, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 90 (1994) 1679-1687
10. Downs J.R., Clearfield M., Tyroler H.A., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998 May 27) 1615-1622
11. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA 288 (2002) 2998
12. Sever P.S., et al., for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
14. Nakamura H., et al., for the MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368 (2006) 1155-1163
15. Shepherd J., Blauw G.J., Murphy M.B., et al. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
16. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study (WOSCOPS) Group. N Engl J Med 333 (1995) 1301
17. Sharp S., and Sterne J. Meta-analysis. Stata Technical Bulletin Reprints 7 STB-38 (1998) 100-108
18. Haldane J. The estimation and significance of the logarithm of a ratio of frequencies. Ann Hum Genet 20 (1955) 309-314
19. Sutton A.J., Abrams K.R., Jones D.R., Sheldon T.A., and Song F. Methods for meta-analysis in medical research (2000), Wiley, Chichester 58
20. Woodward M. Epidemiology, study design and data analysis (1999), Chapman and Hall, London
21. Mantel N., and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22 (1959) 719-748
22. Begg C.B., and Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50 (1994) 1088-1101
23. Egger M., Davey Smith G., Schneider M., and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
24. Knopp R.H., d'Emden M., Smilde J.G., and Pocock S.J. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 29 (2006) 1478-1485
25. Raikou M., McGuire A., Colhoun H.M., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
26. Herd J.A., Ballantyne C.M., Farmer J.A., et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 80 (1997) 278-286
27. Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 72 (1993) 1031-1037
28. Stramba-Badiale M., Fox K.M., Priori S.G., et al. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. Eur Heart J 27 (2006) 994-1005
29. Berger J.S., Roncaglioni M.C., Avanzini F., Pangrazzi I., Tognoni G., and Brown D.L. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 295 (2006) 306-313
30. Thavendiranathan P., Bagai A., Brookhart M.A., and Choudhry N.K. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 166 (2006) 2307-2313
31. Dale K.M., Coleman C.I., Shah S.A., Patel A.A., Kluger J., and White C.M. Impact of gender on statin efficacy. Curr Med Res Opin. 23 (2007) 565-574
32. Coats A.J. Ethical authorship and publishing. Int J Cardiol 131 (2009) 149-150